Guérin E, Entz-Werlé N, Eyer D, Pencreac'h E, Schneider A, Falkenrodt A, Uettwiller F, Babin A, Voegeli A-C, Lessard M, Gaub M-P, Lutz P, Oudet P
Laboratoire de Biochimie et de Biologie Moléculaire Hôpital de Hautepierre, Strasbourg, France.
Leukemia. 2003 Mar;17(3):532-40. doi: 10.1038/sj.leu.2402774.
Topoisomerase genes were analyzed at both DNA and RNA levels in 25 cases of newly diagnosed childhood acute lymphoblastic leukemia (ALL). The results of molecular analysis were compared to risk group classification of children in order to identify molecular characteristics associated with response to therapy. At diagnosis, allelic imbalance at topo-isomerase IIalpha (TOP2A) gene locus was found in 75% of informative cases whereas topoisomerase I and IIbeta gene loci are altered in none or only one case, respectively. By semi-quantitative Polymerase chain reaction, we found a 2.5 to 8-fold TOP2A gene amplification in 72% of the children, which was correlated to gene overexpression in every case. These results show that TOP2A gene amplification is a frequent event in ALL at diagnosis. Interestingly, we also identified a small population of children that do not present TOP2A gene amplification or gene overexpression and who are significantly associated with very high risk classified patients showing glucocorticoid resistance. In conclusion, characterization of TOP2A gene status in childhood ALL at diagnosis provides useful complementary information for risk assessment.
在25例新诊断的儿童急性淋巴细胞白血病(ALL)中,对拓扑异构酶基因进行了DNA和RNA水平的分析。将分子分析结果与儿童风险组分类进行比较,以确定与治疗反应相关的分子特征。诊断时,在75%的信息充分的病例中发现拓扑异构酶IIα(TOP2A)基因位点存在等位基因失衡,而拓扑异构酶I和IIβ基因位点分别在无病例或仅1例中发生改变。通过半定量聚合酶链反应,我们发现72%的儿童中TOP2A基因扩增了2.5至8倍,且在每种情况下均与基因过表达相关。这些结果表明,TOP2A基因扩增在ALL诊断时是常见事件。有趣的是,我们还鉴定出一小部分儿童,他们不存在TOP2A基因扩增或基因过表达,且与显示糖皮质激素抵抗的极高风险分类患者显著相关。总之,诊断时儿童ALL中TOP2A基因状态的特征为风险评估提供了有用的补充信息。